BRPI0414017B8 - pró-fármaco polimérico de múltiplos braços, composição farmacêutica e método para a preparação de um pró-fármaco polimérico de múltiplos braços. - Google Patents
pró-fármaco polimérico de múltiplos braços, composição farmacêutica e método para a preparação de um pró-fármaco polimérico de múltiplos braços.Info
- Publication number
- BRPI0414017B8 BRPI0414017B8 BRPI0414017A BRPI0414017A BRPI0414017B8 BR PI0414017 B8 BRPI0414017 B8 BR PI0414017B8 BR PI0414017 A BRPI0414017 A BR PI0414017A BR PI0414017 A BRPI0414017 A BR PI0414017A BR PI0414017 B8 BRPI0414017 B8 BR PI0414017B8
- Authority
- BR
- Brazil
- Prior art keywords
- prodrugs
- arm polymeric
- polymeric prodrug
- water
- soluble
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title abstract 6
- 239000000651 prodrug Substances 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/595—Polyamides, e.g. nylon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polyethers (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50367303P | 2003-09-17 | 2003-09-17 | |
US60/503,673 | 2003-09-17 | ||
US58430804P | 2004-06-30 | 2004-06-30 | |
US60/584,308 | 2004-06-30 | ||
PCT/US2004/030720 WO2005028539A2 (en) | 2003-09-17 | 2004-09-17 | Multi-arm polymer prodrugs |
Publications (4)
Publication Number | Publication Date |
---|---|
BRPI0414017A BRPI0414017A (pt) | 2006-09-05 |
BRPI0414017A8 BRPI0414017A8 (pt) | 2018-04-24 |
BRPI0414017B1 BRPI0414017B1 (pt) | 2019-04-09 |
BRPI0414017B8 true BRPI0414017B8 (pt) | 2021-05-25 |
Family
ID=34381082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0414017A BRPI0414017B8 (pt) | 2003-09-17 | 2004-09-17 | pró-fármaco polimérico de múltiplos braços, composição farmacêutica e método para a preparação de um pró-fármaco polimérico de múltiplos braços. |
Country Status (18)
Country | Link |
---|---|
US (4) | US7744861B2 (pt) |
EP (2) | EP2626083A1 (pt) |
JP (4) | JP5632119B2 (pt) |
KR (2) | KR101200729B1 (pt) |
CN (2) | CN1852740B (pt) |
AU (2) | AU2004274489B2 (pt) |
BR (1) | BRPI0414017B8 (pt) |
CA (1) | CA2537336C (pt) |
CY (1) | CY1119303T1 (pt) |
DK (1) | DK1675622T3 (pt) |
ES (1) | ES2629696T3 (pt) |
HR (1) | HRP20171094T1 (pt) |
HU (1) | HUE036290T2 (pt) |
LT (1) | LT1675622T (pt) |
PL (1) | PL1675622T3 (pt) |
PT (1) | PT1675622T (pt) |
SI (1) | SI1675622T1 (pt) |
WO (1) | WO2005028539A2 (pt) |
Families Citing this family (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060177416A1 (en) | 2003-10-14 | 2006-08-10 | Medivas, Llc | Polymer particle delivery compositions and methods of use |
US8394813B2 (en) | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
US20060014697A1 (en) * | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
US7169752B2 (en) * | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
US8133881B2 (en) | 2003-01-13 | 2012-03-13 | Shire Llc | Carbohydrate conjugates to prevent abuse of controlled substances |
US7744861B2 (en) | 2003-09-17 | 2010-06-29 | Nektar Therapeutics | Multi-arm polymer prodrugs |
US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
AU2006245107B2 (en) * | 2005-05-11 | 2011-02-10 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of cytidine metabolic antagonist |
US9346029B2 (en) | 2005-06-06 | 2016-05-24 | The University Of British Columbia | Polymer-based serum albumin substitute |
WO2006138463A2 (en) | 2005-06-17 | 2006-12-28 | Nektar Therapeutics Al, Corporation | Polymer-based compositions and conjugates of non-steroidal anti-inflammatory drugs |
WO2007035938A2 (en) | 2005-09-22 | 2007-03-29 | Medivas, Llc | BIS-(α-AMINO)-DIOL-DIESTER-CONTAINING POLY(ESTER AMIDE) AND POLY(ESTER URETHANE) COMPOSITIONS AND METHODS OF USE |
JP5178520B2 (ja) * | 2005-09-22 | 2013-04-10 | メディバス エルエルシー | 固体ポリマー送達組成物およびその使用法 |
WO2007067744A2 (en) * | 2005-12-07 | 2007-06-14 | Medivas, Llc | Method for assembling a polymer-biologic delivery composition |
WO2007070682A2 (en) | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | System for screening particles |
US9603941B2 (en) * | 2006-01-24 | 2017-03-28 | Minghui Chai | Method of preparing dendritic drugs |
US7671067B2 (en) * | 2006-02-09 | 2010-03-02 | Enzon Pharmaceuticals, Inc. | Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin |
AU2007212201B2 (en) * | 2006-02-09 | 2012-09-13 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
US7462627B2 (en) * | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
LT1988910T (lt) | 2006-02-28 | 2018-01-10 | Kodiak Sciences Inc. | Akriloiloksietilfosforilcholiną turintys polimero konjugatai ir jų gavimo būdas |
US20070292476A1 (en) * | 2006-05-02 | 2007-12-20 | Medivas, Llc | Delivery of ophthalmologic agents to the exterior or interior of the eye |
US20070282011A1 (en) * | 2006-05-09 | 2007-12-06 | Medivas, Llc | Biodegradable water soluble polymers |
US8367113B2 (en) | 2006-05-15 | 2013-02-05 | Massachusetts Institute Of Technology | Polymers for functional particles |
WO2007150030A2 (en) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
JP5277417B2 (ja) * | 2006-11-30 | 2013-08-28 | ネクター セラピューティクス | ポリマー複合体を調製する方法 |
AU2008213576B2 (en) * | 2007-02-09 | 2013-01-17 | Enzon Pharmaceuticals, Inc. | Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
WO2008098165A2 (en) | 2007-02-09 | 2008-08-14 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
JP5428017B2 (ja) * | 2007-03-23 | 2014-02-26 | 国立大学法人 熊本大学 | ワクチン剤 |
EP2144600A4 (en) | 2007-04-04 | 2011-03-16 | Massachusetts Inst Technology | POLY (AMINIC ACID) TARGET MOLECULES |
WO2008144067A1 (en) * | 2007-05-21 | 2008-11-27 | Board Of Regents, University Of Texas System | Methods and compositions for treatment of cancer using oncolytic rsv activity |
EP2178944A1 (en) * | 2007-07-24 | 2010-04-28 | Medivas, LLC | Biodegradable cationic polymer gene transfer compositions and methods of use |
EP2192914A4 (en) * | 2007-08-20 | 2014-05-07 | Belrose Pharma Inc | POLYMER BINDERS CONTAINING PYRIDYL DISULFIDE GROUPS |
JP2010536884A (ja) * | 2007-08-23 | 2010-12-02 | メディバス エルエルシー | カチオン性アルファアミノ酸を含有する生分解性ポリマー遺伝子導入組成物 |
US8088884B2 (en) * | 2007-09-27 | 2012-01-03 | Serina Therapeutics, Inc. | Multi-armed forms of activated polyoxazoline and methods of synthesis thereof |
BRPI0817664A2 (pt) | 2007-10-12 | 2015-03-24 | Massachusetts Inst Technology | Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo |
WO2009058387A2 (en) | 2007-11-02 | 2009-05-07 | Nektar Therapeutics Al, Corporation | Oligomer-nitroimidazole anti-infective conjugates |
EP2268315B1 (en) * | 2008-03-31 | 2019-07-31 | Freie Universität Berlin | Drug conjugates with polyglycerols |
EP2216049A1 (en) * | 2009-02-06 | 2010-08-11 | Freie Universität Berlin | Drug conjugates with polyglycerols |
JP2011516503A (ja) * | 2008-04-07 | 2011-05-26 | インターフェース バイオロジクス,インコーポレーテッド | 細菌感染症を治療するための併用療法 |
AU2009282413B2 (en) | 2008-08-11 | 2014-07-17 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
JP2012500207A (ja) * | 2008-08-13 | 2012-01-05 | メディバス エルエルシー | Aabb−ポリ(デプシペプチド)生分解性ポリマー及び使用方法 |
TW201010732A (en) * | 2008-08-29 | 2010-03-16 | Enzon Pharmaceuticals Inc | Method of treating RAS associated cancer |
US20110165112A1 (en) * | 2008-09-19 | 2011-07-07 | Nektar Therapeutics | Polymer conjugates of c-peptides |
EP2341942A1 (en) | 2008-09-19 | 2011-07-13 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
MX2011003063A (es) * | 2008-09-23 | 2011-04-21 | Nektar Therapeutics | Composiciones y metodos para lograr concentraciones terapeuticas de farmaco sostenidas en un individuo. |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US20100098654A1 (en) * | 2008-10-21 | 2010-04-22 | Fabio Pastorino | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
KR20100083632A (ko) * | 2009-01-14 | 2010-07-22 | 울산대학교 산학협력단 | 표적 단백질 분해효소 감응형 항암제 전구체 |
JP2012526049A (ja) * | 2009-05-04 | 2012-10-25 | インテザイン テクノロジーズ, インコーポレイテッド | 腫瘍治療のためのsn−38を含有するポリマーミセル |
BR112012001395A2 (pt) * | 2009-07-22 | 2019-09-24 | Enzon Pharmaceuticals Inc | metodo para tratar um câncer her2 positivo em um mamifero metodo para aumentar os efetivos de antagonistas do receptor her2 em um mamifero apresentando um cancêr her2 positivo metodo para inibir o crescimento ou proliferação de células her2 positivas em um mamifero |
US8722732B2 (en) | 2009-09-29 | 2014-05-13 | Nektar Therapeutics | Oligomer-calcimimetic conjugates and related compounds |
PT2501413T (pt) | 2009-11-18 | 2019-07-10 | Nektar Therapeutics | Formas de sal de ácido de conjugados de polímero-fármaco |
WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
CN102906157B (zh) | 2010-03-01 | 2016-08-24 | 不列颠哥伦比亚大学 | 衍生的超支化聚丙三醇 |
NZ603399A (en) * | 2010-05-17 | 2014-09-26 | Cebix Inc | Pegylated c-peptide |
CN102339813A (zh) | 2010-07-14 | 2012-02-01 | 中国科学院微电子研究所 | 半导体结构及其制造方法 |
US20120016390A1 (en) * | 2010-07-16 | 2012-01-19 | Knc Ner Acquisition Sub, Inc. | Bioadhesive compounds and methods of synthesis and use |
AU2011282983A1 (en) * | 2010-07-28 | 2013-02-21 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
US8524215B2 (en) * | 2010-08-02 | 2013-09-03 | Janssen Biotech, Inc. | Absorbable PEG-based hydrogels |
US20140371258A1 (en) * | 2010-12-17 | 2014-12-18 | Nektar Therapeutics | Water-Soluble Polymer Conjugates of Topotecan |
JP5899241B2 (ja) * | 2010-12-21 | 2016-04-06 | ネクター セラピューティクス | ペメトレキセドベースの化合物のマルチアームポリマープロドラッグコンジュゲート |
WO2012088422A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
WO2012088445A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
US10220020B2 (en) | 2010-12-23 | 2019-03-05 | Nektar Therapeutics | Polymer-des-ethyl sunitinib conjugates |
US9827326B2 (en) | 2010-12-23 | 2017-11-28 | Nektar Therapeutics | Polymer-sunitinib conjugates |
CA2836915A1 (en) | 2011-05-20 | 2012-11-29 | Howard University | Emetine derivatives, prodrugs containing same, and methods of treating conditions using same |
WO2012166555A1 (en) | 2011-05-27 | 2012-12-06 | Nektar Therapeutics | Water - soluble polymer - linked binding moiety and drug compounds |
US11123364B2 (en) | 2011-06-21 | 2021-09-21 | Bvw Holding Ag | Medical device comprising boswellic acid |
US9873764B2 (en) | 2011-06-23 | 2018-01-23 | Dsm Ip Assets, B.V. | Particles comprising polyesteramide copolymers for drug delivery |
US9873765B2 (en) | 2011-06-23 | 2018-01-23 | Dsm Ip Assets, B.V. | Biodegradable polyesteramide copolymers for drug delivery |
US20140296257A1 (en) | 2011-08-12 | 2014-10-02 | Ascendis Pharma A/S | High-Loading Water-Soluable Carrier-Linked Prodrugs |
US20140243254A1 (en) | 2011-08-12 | 2014-08-28 | Ascendis Pharma A/S | Polymeric Hyperbranched Carrier-Linked Prodrugs |
CN102935066B (zh) * | 2011-08-16 | 2014-09-17 | 齐鲁制药有限公司 | 一种伊立替康脂质体制剂及其制备方法 |
EP2771034B1 (en) * | 2011-10-25 | 2018-08-08 | Nektar Therapeutics | Topoisomerase-i and-ii inhibitors for use in the treatment of patients suffering from cancer |
US8383093B1 (en) * | 2011-11-01 | 2013-02-26 | Serina Therapeutics, Inc. | Subcutaneous delivery of poly(oxazoline) conjugates |
CN103083680B (zh) | 2011-11-07 | 2014-12-24 | 北京键凯科技有限公司 | 聚乙二醇-氨基酸寡肽-依诺替康药物结合物及其药物组合物 |
RU2493848C1 (ru) * | 2012-06-14 | 2013-09-27 | Геннадий Петрович Власов | Биодеградируемый полимерный носитель для доставки противоопухолевого лекарственного средства (варианты) |
JP6300460B2 (ja) * | 2012-07-20 | 2018-03-28 | キヤノン株式会社 | 化合物、および前記化合物を有する光音響イメージング用造影剤 |
EP2926137B1 (en) * | 2012-11-28 | 2019-05-29 | Nektar Therapeutics | Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase i inhibitor |
US9863949B2 (en) | 2013-05-31 | 2018-01-09 | Nektar Therapeutics | Method for predicting and evaluating responsiveness to cancer treatment with DNA-damaging chemotherapeutic agents |
EP3027026A4 (en) | 2013-07-31 | 2017-05-03 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
WO2015023675A2 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US10702608B2 (en) | 2013-09-08 | 2020-07-07 | Kodiak Sciences Inc. | Factor VIII zwitterionic polymer conjugates |
JP5721806B2 (ja) | 2013-10-04 | 2015-05-20 | Delta−Fly Pharma株式会社 | 副作用のない抗癌剤 |
TWI716342B (zh) | 2013-10-04 | 2021-01-21 | 美商普洛林克斯有限責任公司 | Sn-38之緩釋結合物 |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10653689B2 (en) * | 2014-01-14 | 2020-05-19 | Nektar Therapeutics | Combination-based treatment method |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
AU2015290098B2 (en) | 2014-07-17 | 2018-11-01 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
CN107208076A (zh) | 2014-10-17 | 2017-09-26 | 科达制药 | 丁酰胆碱酯酶两性离子聚合物缀合物 |
JP2017531026A (ja) | 2014-10-20 | 2017-10-19 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 徐放性乱用抑止性液体充填剤形 |
CN107001617B (zh) | 2014-12-04 | 2019-08-27 | 德鲁塔负富莱制药股份有限公司 | Peg衍生物 |
AU2015366355B2 (en) | 2014-12-18 | 2020-05-28 | Dsm Ip Assets B.V. | Drug delivery system for delivery of acid sensitive drugs |
CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
CN107375288B (zh) * | 2016-05-16 | 2019-08-23 | 博瑞生物医药(苏州)股份有限公司 | 多臂的聚合靶向抗癌偶联物 |
ES2910987T3 (es) * | 2016-08-09 | 2022-05-17 | Univ Liverpool | Composiciones oftálmicas |
MX2019008276A (es) | 2017-01-10 | 2019-09-16 | Nektar Therapeutics | Conjugados de polimero multibrazo de compuestos agonistas de tlr y metodos de tratamiento inmunoterapeutico relacionados. |
JP2020105072A (ja) * | 2017-03-24 | 2020-07-09 | 協和キリン株式会社 | ポリエチレングリコール誘導体 |
CN108727584B (zh) * | 2017-04-21 | 2021-01-05 | 博瑞生物医药(苏州)股份有限公司 | 抗癌偶联物 |
WO2018192550A1 (zh) | 2017-04-21 | 2018-10-25 | 博瑞生物医药(苏州)股份有限公司 | 多臂靶向抗癌偶联物 |
MA49578A (fr) | 2017-07-11 | 2021-04-07 | Synthorx Inc | Incorporation de nucléotides non naturels et procédés associés |
NZ761430A (en) | 2017-08-03 | 2024-03-22 | Synthorx Inc | Cytokine conjugates for the treatment of proliferative and infectious diseases |
CN109771658B (zh) * | 2017-11-14 | 2021-12-10 | 博瑞生物医药(苏州)股份有限公司 | 靶向多臂偶联物 |
CN109776788B (zh) * | 2017-11-14 | 2021-07-30 | 博瑞生物医药(苏州)股份有限公司 | 叶酸受体靶向多臂偶联物 |
CN109776787B (zh) * | 2017-11-14 | 2021-08-03 | 博瑞生物医药(苏州)股份有限公司 | 多臂靶向偶联物 |
WO2019096096A1 (zh) * | 2017-11-14 | 2019-05-23 | 博瑞生物医药(苏州)股份有限公司 | 多臂靶向偶联物 |
EP3737430A4 (en) * | 2018-01-08 | 2021-10-06 | The Regents Of The University Of Colorado | THREE-DIMENSIONAL IN VITRO MODELS OF LUNG TISSUE |
US20200360545A1 (en) | 2018-01-12 | 2020-11-19 | Prolynx Llc | Protocol for minimizing toxicity of combination dosages and imaging agent for verification |
AU2019344783A1 (en) | 2018-09-17 | 2021-04-08 | The Children's Hospital Of Philadelphia | Polymer-based macromolecular prodrugs |
WO2020081684A1 (en) * | 2018-10-16 | 2020-04-23 | Rensselaer Polytechnic Institute | Synthesis and processing of poly(pro-drug) materials for extended drug release and uses thereof |
KR20210123299A (ko) | 2019-02-06 | 2021-10-13 | 신톡스, 인크. | Il-2 콘쥬게이트 및 이의 사용 방법 |
CN111603567A (zh) | 2019-02-22 | 2020-09-01 | 博瑞生物医药(苏州)股份有限公司 | Cd44靶向多臂偶联物 |
EP3969488A1 (en) * | 2019-08-28 | 2022-03-23 | Boston Scientific Scimed Inc. | Multi-armed polymers comprising free-radical-polymerizable monomers |
CN118325079A (zh) * | 2019-08-28 | 2024-07-12 | 波士顿科学国际有限公司 | 多臂聚恶唑啉和与其相关的组合物、***和方法 |
JP2022547078A (ja) | 2019-09-10 | 2022-11-10 | シンソークス, インコーポレイテッド | Il-2コンジュゲートおよび自己免疫疾患を治療するための使用方法 |
CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
WO2021091986A1 (en) | 2019-11-04 | 2021-05-14 | Synthorx, Inc. | Interleukin 10 conjugates and uses thereof |
CN113164474B (zh) * | 2020-05-14 | 2022-07-15 | 德尔塔菲制药股份有限公司 | 维奈托克的水溶性高分子衍生物 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
AU4406793A (en) * | 1992-06-04 | 1993-12-30 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
US5614549A (en) * | 1992-08-21 | 1997-03-25 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5880131A (en) * | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5965566A (en) * | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5605976A (en) * | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5629384A (en) | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
TW438775B (en) * | 1995-04-07 | 2001-06-07 | Pharmacia & Upjohn Co Llc | Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds |
US5726181A (en) * | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
EP0886648B8 (en) | 1995-06-07 | 2004-03-03 | Ortho Pharmaceutical Corporation | Compounds and peptides that bind to the erythropoietin receptor |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
SG50747A1 (en) * | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
AU735900B2 (en) | 1996-03-12 | 2001-07-19 | Pg-Txl Company, L.P. | Water soluble paclitaxel prodrugs |
FR2746308B1 (fr) | 1996-03-22 | 1998-04-30 | Oreal | Compositions de teinture des fibres keratiniques contenant des imidazolo-azoles ; leur utilisation en teinture comme coupleurs ; procede de teinture |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6011042A (en) * | 1997-10-10 | 2000-01-04 | Enzon, Inc. | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds |
US6111107A (en) * | 1997-11-20 | 2000-08-29 | Enzon, Inc. | High yield method for stereoselective acylation of tertiary alcohols |
US6624142B2 (en) * | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
US6362254B2 (en) | 1998-03-12 | 2002-03-26 | Shearwater Corporation | Poly(ethylene glycol) derivatives with proximal reactive groups |
US6153655A (en) * | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
DE29812626U1 (de) | 1998-07-15 | 1998-11-12 | SCM Microsystems GmbH, 85276 Pfaffenhofen | Kartenleser für Chipkarten |
WO2000064486A2 (en) | 1999-04-28 | 2000-11-02 | Vectramed, Inc. | Enzymatically activated polymeric drug conjugates |
WO2000066125A1 (en) * | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
US6541508B2 (en) | 1999-09-13 | 2003-04-01 | Nobex Corporation | Taxane prodrugs |
DK1259562T3 (da) * | 1999-12-22 | 2006-04-18 | Nektar Therapeutics Al Corp | Sterisk hindrede derivater af vandoplöselige polymerer |
US20040009229A1 (en) * | 2000-01-05 | 2004-01-15 | Unger Evan Charles | Stabilized nanoparticle formulations of camptotheca derivatives |
WO2001062827A2 (en) * | 2000-02-22 | 2001-08-30 | Shearwater Corporation | N-maleimidyl polymer derivatives |
AU2001257577A1 (en) * | 2000-02-28 | 2001-09-03 | Shearwater Corporation | Water-soluble polymer conjugates of artelinic acid |
US6777387B2 (en) | 2000-03-31 | 2004-08-17 | Enzon Pharmaceuticals, Inc. | Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same |
US6629995B1 (en) | 2000-03-31 | 2003-10-07 | Super Gen, Inc. | Camptothecin conjugates |
US6756037B2 (en) | 2000-03-31 | 2004-06-29 | Enzon, Inc. | Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups |
DK1301808T3 (da) | 2000-07-21 | 2010-04-06 | Schlumberger Technology Bv | Fremgangsmåde og apparat til analyse af kernemagnetiske resonansdata |
JP2004514701A (ja) | 2000-11-30 | 2004-05-20 | ネクター セラピューティクス エーエル,コーポレイション | トリアジン誘導体の水溶性ポリマー複合体 |
EP1427407A4 (en) * | 2001-03-23 | 2005-05-11 | Luitpold Pharm Inc | CONJUGATES BASED ON FATTY AMINES AND PHARMACEUTICAL AGENTS |
US20030108556A1 (en) * | 2001-06-08 | 2003-06-12 | Mekalanos John J. | Therapeutic uses of polyvalent compositions in infectious diseases |
WO2003033525A1 (en) | 2001-10-12 | 2003-04-24 | Debio Recherche Pharmacuetique S.A. | Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament |
EP1441772A2 (en) * | 2001-10-29 | 2004-08-04 | Nektar Therapeutics Al, Corporation | Polymer conjugates of protein kinase c inhibitors |
MXPA04004025A (es) * | 2001-10-30 | 2004-07-08 | Nektar Therapeutics Al Corp | Conjugados polimericos de acido retinoico solubles en agua. |
US6608076B1 (en) * | 2002-05-16 | 2003-08-19 | Enzon, Inc. | Camptothecin derivatives and polymeric conjugates thereof |
JP2005529938A (ja) * | 2002-06-06 | 2005-10-06 | ユニバーシティ オブ ワシントン | 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法 |
US7122189B2 (en) * | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
MX367615B (es) * | 2002-09-06 | 2019-08-28 | Cerulean Pharma Inc | Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos. |
US7744861B2 (en) | 2003-09-17 | 2010-06-29 | Nektar Therapeutics | Multi-arm polymer prodrugs |
-
2004
- 2004-09-17 US US10/943,799 patent/US7744861B2/en active Active
- 2004-09-17 LT LTEP04784560.7T patent/LT1675622T/lt unknown
- 2004-09-17 KR KR1020067007403A patent/KR101200729B1/ko active IP Right Grant
- 2004-09-17 PL PL04784560T patent/PL1675622T3/pl unknown
- 2004-09-17 CN CN2004800268096A patent/CN1852740B/zh active Active
- 2004-09-17 DK DK04784560.7T patent/DK1675622T3/en active
- 2004-09-17 JP JP2006527105A patent/JP5632119B2/ja not_active Expired - Fee Related
- 2004-09-17 SI SI200432402T patent/SI1675622T1/sl unknown
- 2004-09-17 EP EP13164490.8A patent/EP2626083A1/en not_active Withdrawn
- 2004-09-17 PT PT47845607T patent/PT1675622T/pt unknown
- 2004-09-17 AU AU2004274489A patent/AU2004274489B2/en not_active Ceased
- 2004-09-17 WO PCT/US2004/030720 patent/WO2005028539A2/en active Application Filing
- 2004-09-17 CN CN201110070872.1A patent/CN102172405B/zh active Active
- 2004-09-17 HU HUE04784560A patent/HUE036290T2/hu unknown
- 2004-09-17 BR BRPI0414017A patent/BRPI0414017B8/pt not_active IP Right Cessation
- 2004-09-17 EP EP04784560.7A patent/EP1675622B1/en active Active
- 2004-09-17 KR KR1020127015575A patent/KR20120073370A/ko not_active Application Discontinuation
- 2004-09-17 ES ES04784560.7T patent/ES2629696T3/es active Active
- 2004-09-17 CA CA2537336A patent/CA2537336C/en active Active
-
2008
- 2008-02-11 US US12/069,727 patent/US20080194612A1/en not_active Abandoned
-
2010
- 2010-02-22 US US12/709,800 patent/US8263062B2/en active Active
- 2010-03-19 US US12/728,072 patent/US8318145B2/en active Active
-
2011
- 2011-05-24 AU AU2011202402A patent/AU2011202402B2/en not_active Ceased
- 2011-06-21 JP JP2011137790A patent/JP6166014B2/ja not_active Expired - Fee Related
-
2014
- 2014-06-10 JP JP2014119823A patent/JP2014196321A/ja active Pending
-
2017
- 2017-03-13 JP JP2017047691A patent/JP2017119706A/ja active Pending
- 2017-07-17 HR HRP20171094TT patent/HRP20171094T1/hr unknown
- 2017-08-17 CY CY20171100875T patent/CY1119303T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0414017B8 (pt) | pró-fármaco polimérico de múltiplos braços, composição farmacêutica e método para a preparação de um pró-fármaco polimérico de múltiplos braços. | |
WO2011079279A3 (en) | Nanoconjugates and nanoconjugate formulations | |
BRPI0911442A2 (pt) | conjugados potentes e ligantes hidrofílicos | |
MY167123A (en) | Conveniently implantable sustained release drug compositions | |
BR0113663A (pt) | Composições de pelìcula de pectina | |
CY1116075T1 (el) | Νεες συνθεσεις λιποσωματων | |
BRPI0621656B8 (pt) | misturas binárias de ácido hialurônico e uso terapêutico destas | |
BRPI0414000B8 (pt) | composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica | |
DE60144281D1 (de) | Neues kationisches lipopolymer als biokompatible gentransfer-mittel | |
CY1115891T1 (el) | Φαρμακευτικες συνθεσεις για την αντιμετωπιση των διαταραχων του εσω ωτος | |
CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
WO2007027941A3 (en) | Compositions and methods for preparation of poorly water soluble drugs with increased stability | |
CY1115526T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει πιμοβενδανη | |
WO2007100902A3 (en) | Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation | |
BR0212475A (pt) | Composições farmacêuticas | |
WO2010039496A3 (en) | Nanocarriers for drug delivery | |
WO2006110776A3 (en) | Polyethylene glycol cojugates of antimicrobial agents | |
DK1318788T3 (da) | Nanopartikulær fastdosissammensætninger | |
EA200900155A1 (ru) | Модуляторы фармакокинетических свойств лекарственных средств | |
WO2005072343A3 (en) | Aqueous pharmaceutical compositions 2,6-diisopropylphenol (propofol) and their use | |
ME00969B (me) | Citotoksična sredstva koja uključuju nove derivate tomajmicina i njihova upotreba u terapiji | |
WO2008085556A3 (en) | Surfactant-free nanoparticles for drug delivery | |
CY1113824T1 (el) | Ενδορινικες συνθεσεις | |
ATE426635T1 (de) | Arzneimittelverabreichung | |
NO20083573L (no) | Amfifile polymerer for opploseliggjoring og malrettet avgivelse av legemidler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: C08L 71/02 (2006.01), A61K 47/58 (2017.01), A61K 4 |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/09/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B25A | Requested transfer of rights approved |
Owner name: NEKTAR THERAPEUTICS (US) |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 20A ANUIDADE. |